febuxostat has been researched along with Cachexia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iino, T; Matsumine, A; Nakamura, T; Odake, K; Sudo, A; Tsujii, M; Tsukamoto, T | 1 |
| Hisaka, A; Kurebayashi, N; Miyano, K; Nonaka, M; Sakurai, T; Sato, H; Uezono, Y; Uzu, M; Yanagihara, K | 1 |
2 other study(ies) available for febuxostat and Cachexia
| Article | Year |
|---|---|
Febuxostat reduces muscle wasting in tumor-bearing mice with LM8 osteosarcoma cells via inhibition of reactive oxygen species generation.
Topics: Animals; Apoptosis; Bone Neoplasms; Cachexia; Cell Proliferation; Febuxostat; Gout Suppressants; Humans; Male; Mice; Mice, Inbred C3H; Osteosarcoma; Oxidative Stress; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain.
Topics: Administration, Oral; Animals; Brain; Cachexia; Disease Models, Animal; Febuxostat; Male; Mice, Inbred BALB C; Neoplasms; Purines; Xanthine Oxidase | 2019 |